Avicanna Inc. (AVCNF)

Overview

Avicanna Inc. is a pioneering biopharmaceutical entity focused on the development, research, and commercialization of innovative cannabinoid-based products. Catering to both the consumer and medical spheres, as well as the pharmaceutical industry on a global scale, Avicanna is at the forefront of leveraging evidence-based approaches to harness the potential of cannabinoids. Since its inception in 2016, with headquarters situated in Toronto, Canada, Avicanna has established itself as a leader in the cannabinoid research field, offering a wide range of proprietary products designed to meet various medical, consumer, and pharmaceutical needs. Through rigorous scientific exploration and a commitment to advancing cannabinoid science, Avicanna aims to address unmet medical needs and improve the quality of life for individuals worldwide.

Products and Services

• RHO Phyto: This is Avicanna's line of medical cannabis formulations, which includes a variety of delivery mechanisms such as oral, sublingual, topical, and transdermal products. These offerings boast different ratios of cannabinoids, aimed at providing targeted relief and addressing specific medical conditions efficiently.
• Pharmaceutical Products: Avicanna is also dedicated to the development of indication-specific pharmaceutical products. Among these is Trunerox, an adjuvant treatment for seizures that occur with Lennox-Gastaut Syndrome and Dravet Syndrome, showcasing the company's commitment to tackling severe neurological disorders through innovative cannabinoid-based therapies.
• Active Pharmaceutical Ingredients (APIs): Under the Aureus Santa Marta brand, Avicanna offers a range of CBD, THC, and CBG ingredients. These APIs are integral for the development and manufacturing of various products across the food, cosmetic, medical, and pharmaceutical industries, highlighting Avicanna's versatility and broad impact.
• MyMedi.ca Platform: This medical cannabis care platform underscores Avicanna’s dedication to comprehensive patient support. Offering a wide array of products along with bilingual pharmacist-led support, MyMedi.ca serves veterans, educates the medical community, and facilitates the integration of cannabis into healthcare practices. It stands out for its specialized services and educational resources.
• Collaborations and Research: Avicanna’s commitment to innovation is further exhibited through its research and collaboration agreement with a leading European pharmaceutical company. This partnership focuses on assessing Avicanna’s proprietary SEDDS technology in conjunction with various drug delivery systems, paving the way for novel pharmaceutical applications and formulations.